Also, for high-risk populations, especially for pre-HSCT MRD-positive patients, Haplo-HSCT can mediate a more substantial graft-versus-leukemia (GVL) effect than HLA-matched sibling donor transplantation [22,23,24], making it a promising treatment option for AML patients with RUNX1 mutations. This evidence concerns the gene RUNX1 and leukemia.